1. Introduction {#s0005}
===============

With the discovery and clinical descriptions of the *C9orf72* gene expansion, it has become clear that such carriers may develop psychotic features and in some instances present with florid delusions or hallucinations ([@bb0205]; [@bb0075]). As such, we have seen renewed interest in psychosis in the Frontotemporal dementia-Amyotrophic lateral sclerosis (FTD-ALS) continuum, with recent systematic reviews of the literature suggesting that the prevalence is approximately 10--25% ([@bb0110], [@bb0200]). Neuroimaging studies of the *C9orf72* expansion in both FTD and ALS have highlighted an excess of subcortical atrophy in comparison to non-carriers, and have led researchers to postulate that perhaps subcortical structures play a role in the generation of psychotic symptoms in *C9orf72* cases but up until now this theory has not been explored ([@bb0040], [@bb0085], [@bb0145]). The largest body of evidence regarding psychosis and associated brain abnormalities comes from the literature in schizophrenia and related psychotic disorders, where abnormal changes in the volume, connectivity and function of the frontal and temporal cortices, thalamus and cerebellum have been reported ([@bb0025], [@bb0060], [@bb0095]). These findings may be relevant to psychosis in FTD and FTD-ALS where similar cortical and subcortical regions are involved ([@bb0140]).

The present study aimed to improve our understanding of psychosis across a well-characterised cohort of FTD and FTD-ALS patients, including a subset of *C9orf72* carriers, by collecting prospective data using a validated behavioural tool in combination with a clinical interview. We then determined the underlying neural correlates of psychosis using structural neuroimaging techniques. It was hypothesised that, similar to other psychotic disorders, and in line with imaging studies of *C9orf72* patients, an extended network of cortical and subcortical regions would play a role in the generation of psychosis in FTD.

2. Methods {#s0010}
==========

2.1. Participants {#s0015}
-----------------

In total 79 participants were included in the study; 36 consecutive patients with behavioural variant FTD (bvFTD) and 20 consecutive patients with bvFTD in combination with ALS (FTD-ALS) were matched by sex-, age- and education history to 23 healthy controls. Patients were assessed at ForeFront, the Frontotemporal Dementia Research Group at Neuroscience Research Australia (NeuRA) and the Brain and Mind Centre, between 2008 and 2013. Healthy controls were selected from a volunteer panel at NeuRA.

Diagnosis of bvFTD was made by an experienced clinical neurologist based on international diagnostic criteria for bvFTD ([@bb0175]). ALS was diagnosed by an experienced clinical neurologist according to the El Escorial and Awaji diagnostic criteria ([@bb0055], [@bb0170]). Global cognitive function was measured using the Addenbrooke\'s Cognitive Examination-Revised (ACE-R) ([@bb0155]). Disease staging was assessed with the FTD Functional Rating Scale (FTD-FRS) ([@bb0160]).

In each participant psychotic features began within a 10-year period prior to meeting consensus criteria for FTD. We intended to exclude participants if they were diagnosed with schizophrenia or another delusional disorder by a psychiatrist \> 10 years prior to presentation but this did not apply to these cases. Exclusion criteria also included a past history of traumatic brain injury, drug or alcohol abuse and cerebrovascular disease. None of the patients in the study were taking anti-psychotic medication or psychosis-inducing medication at the time of their initial assessments. Patients were not systematically assessed for hypoxia however this study was conducted at first presentation and at this stage none of the patients required non-invasive ventilation.

Ethical approval was obtained from the South Eastern Sydney and Illawarra Area Health Service and the University of New South Wales ethics committees. All participants, or their responsible person, provided informed written consent in accordance with the Declaration of Helsinki.

2.2. Genetic status {#s0020}
-------------------

All participants underwent blood sampling for the *C9orf72* expansion. The repeat primed PCR was performed using the procedure described previously ([@bb0080]), based on the protocol of Renton and colleagues ([@bb0180]). A patient\'s DNA sample was deemed positive for the *C9orf72* repeat expansion if it contained an allele with \> 30 repeats. Patients with a family history were also screened for other common genetic mutations (*GRN*, *MAPT*) by Sanger sequencing of genomic DNAs corresponding to all coding exons ([@bb0190], [@bb0210]).

2.3. Presence of delusions and hallucinations {#s0025}
---------------------------------------------

A delusion was defined as a false belief based on incorrect inference about external reality that is firmly sustained despite what almost everybody else believes and despite what constitutes incontrovertible and obvious proof or evidence to the contrary. The belief is not ordinarily accepted by other members of the person\'s culture or subculture. A hallucination was defined as a perception of an external stimulus when none is present but which the person believes to be real ([@bb0015]).

The presence of delusions and hallucinations was determined in two ways. Firstly, the delusions and hallucinations subscale of the Neuropsychiatric Inventory (NPI) ([@bb0065]) was completed with the carer. The subscales assess delusions and hallucinations separately with regards to frequency and severity of symptoms. Frequency is scored from 0 to 4; 0 = never, 1 = rarely -- less than once per week, 2 = sometimes -- about once per week, 3 = often -- a few times per week, 4 = frequently -- once or more per day. Severity is scored from 0 to 3; with 0 representing never, 1 = mild -- produces little distress, 2 = moderate -- more disturbing to the patient but can be redirected by the caregiver, 3 = severe -- very disturbing to the patient and difficult to redirect.

During the visit, the nature of abnormal behaviours was clarified with the carer and patient, and re-scored according to the subscales of the NPI. A revised score was derived from the carer and patient interview. A total score was then generated for psychosis to reflect severity of psychotic symptoms by combining delusions (maximum 12) and hallucinations (maximum 12) scores for each participant and then expressing it as a percentage of the total score for delusions and hallucinations (maximum 24), referred to as the 'psychosis index'.

2.4. Image acquisition and pre-processing {#s0030}
-----------------------------------------

All participants underwent whole-brain T1 imaging using a 3T Philips scanner with standard quadrature head coil. The 3D T1-weighted sequences were acquired as follows: coronal orientation, matrix 256 × 256, 200 slices, 1 mm^2^ in-plane resolution, 1 mm slice thickness, echo time/repetition time = 2.6/5.8 ms, flip angle 8°. MRI scans were obtained within 2 days of the clinical interview.

Three-dimensional T1-weighted sequences were analyzed with FSL-VBM (<http://www.fmrib.ox.ac.uk/fsl/fslvbm/index.html>) ([@bb0030]). Structural images were brain-extracted using BET and tissue segmentation was carried out using FMRIB\'s Automatic Segmentation Tool (FAST) ([@bb0225]). The resulting grey matter partial volume maps were then aligned to the Montreal Neurological Institute standard space (MNI 152) using the non-linear registration approach (FNIRT) ([@bb0020]) using a b-spline representation of the registration warp field ([@bb0185]). A study-specific template was created and the native grey matter images were non-linearly re-registered. The registered partial volume maps were modulated (to correct for local expansion or contraction) by dividing them by the Jacobian of the warp field. The modulated images were then smoothed with an isotropic Gaussian kernel with a standard deviation of 3 mm (full-width at half-maximum: 8 mm).

2.5. Statistical analyses {#s0035}
-------------------------

Statistical analyses compared patients with controls irrespective of genetic status (bvFTD and FTD-ALS). Further comparisons between patients groups were carried out according to genetic status (*C9orf72* carriers vs. non-carriers) and presence or absence of psychotic features.

### 2.5.1. Behavioural analyses {#s0040}

Data were analyzed using SPSS 22.0 statistical package. Kolmogorov-Smirnoff tests were applied to determine if clinical and demographic variables were normally distributed. Parametric variables were analyzed using univariate ANOVA, with post hoc analyses comparing differences across groups, using Sidak correction for multiple comparisons. Non-parametric data was analyzed using Mann-Whitney and the Kruskal-Wallis tests, and categorical data were compared with Chi-Square tests.

### 2.5.2. Voxel-based morphometry analyses {#s0045}

First, atrophy analyses were carried out to identify differences in grey matter intensity between patients groups and healthy controls according to clinical diagnosis (bvFTD and FTD-ALS) and genotype (*C9orf72* carriers vs. non-carriers). Voxel-wise general linear models and *t*-tests were applied using permutation-based, non-parametric statistics, with 5000 permutations per contrast ([@bb0165]). Significant clusters were defined at a t-threshold corrected for family-wise error of *p* \< 0.05 with a minimum cluster size of 50 voxels.

Next, correlations between psychosis index scores and grey matter intensity were investigated using an unbiased whole-brain approach. First, to uncover the neural correlates of psychosis in FTD, correlations between demeaned psychosis index scores and grey matter intensity were assessed combining all patients together (bvFTD, FTD-ALS). Then, correlations between psychosis index and grey matter intensity were investigated, using the same analyses described above, in *C9orf72* expansion carriers to identify neural correlates of psychosis specific to this genetic expansion. For all analyses, the statistical threshold was set at *p* \< 0.005 uncorrected for multiple comparisons with a conservative cluster extent threshold of 25 voxels. This approach is designed to minimize Type I error while balancing the risk of Type II error ([@bb0130]). Anatomical locations of significant results were overlaid on the Montreal Neurological Institute (MNI) standard brain within the mricron software (<http://www.mccauslandcenter.sc.edu/mricro/mricron/index.html>), with maximum coordinates provided in MNI stereotaxic space. Anatomical labels were determined with reference to the Harvard-Oxford probabilistic cortical and subcortical atlases.

3. Results {#s0050}
==========

3.1. Demographics, cognitive and behavioural screening measures {#s0055}
---------------------------------------------------------------

A comparison of the patient groups (bvFTD and FTD-ALS) with healthy controls revealed a higher ACE-R score for controls compared to patients. Otherwise there were no significant differences across the groups for age, sex and education years. Within the patient groups bvFTD patients scored lower in the FRS, indicating more functional impairment. Of the 56 patients included in the study 25% were *C9orf72* expansion carriers. No patients carried *GRN* or *MAPT* mutations. Comparison between *C9orf72* carriers and non-carriers revealed no significant differences across demographic, cognitive and functional measures (all *p* \> 0.05) ([Table 1](#t0005){ref-type="table"}).

3.2. Psychotic features {#s0060}
-----------------------

### 3.2.1. Neuropsychiatric inventory {#s0065}

Of the 56 patients, 34% showed psychotic features; 28% experienced delusions while 25% experienced hallucinations. There were no significant differences between patients with and without psychosis for all demographic variables (all *p* \> 0.05; Table e1). Furthermore, there were no significant differences between patients with and without psychosis, for NPI scores of disinhibition, apathy, depression, anxiety, agitation, elation, irritability, appetite or sleep (all *p* \> 0.1).

### 3.2.2. Psychosis index {#s0070}

Exactly 64% of *C9orf72* expansion carriers exhibited psychotic symptoms compared to 26% of non-carriers (*p* = 0.006). The psychosis index was 12 in the overall patient cohort and was significantly higher in the *C9orf72* positive cohort than the *C9orf72* negative cohort (*p* = 0.002; [Table 2](#t0010){ref-type="table"}).

### 3.2.3. Characterisation of psychosis {#s0075}

Delusions were characterised according to their content and following accepted criteria ([@bb0115]). Persecutory delusions were the most common and were present in 63% of all affected patients. Somatic delusions (31%), delusions of a jealous nature (19%) and grandiose delusions (25%) were also present. In total, 38% of patients had a mixture of the above delusion types.

Hallucinations were characterised according to modality. Auditory hallucinations were all in the second person and of a negative and persecutory nature. Visual hallucinations were either in the form of people, both alive and dead, or animals. Tactile hallucinations were of human touch in one and of insects crawling under the skin in another.

Hallucinations and delusions in the *C9orf72* cohort were similar to that seen in the patient cohort as a whole ([Table 2](#t0010){ref-type="table"}), however there were no significant differences in the rate of hallucinations between carriers and non-carriers. Of note, somatic delusions were common in *C9orf72* carriers and included medically unexplained sensory disturbances and abdominal pains.

3.3. Neuroimaging results {#s0080}
-------------------------

### 3.3.1. Atrophy analyses {#s0085}

Group comparisons between clinical diagnoses and controls revealed the characteristic profiles of brain atrophy previously reported in bvFTD and FTD-ALS ([@bb0140]). These results are presented in Supplementary Fig. e1. In brief, both patient groups showed extensive overlap of grey matter density loss with widespread atrophy predominantly in frontal and temporal regions including the anterior insula, orbitofrontal cortex, striatum, thalamus and temporal poles. Parietal and occipital regions and the cerebellum were also involved. Direct comparisons between bvFTD and FTD-ALS revealed no significant regions of greater grey matter loss in either group.

Consistent with previous studies in both FTD and ALS, patients with and without *C9orf72* expansions showed overlapping but distinct atrophy patterns ([@bb0035], [@bb0045], [@bb0145], [@bb0220]). *C9orf72* expansion carriers showed atrophy in bilateral anterior cingulate, dorsolateral and orbitofrontal prefrontal cortex, insular cortices and lateral parietal cortices, striatum and bilateral thalamus compared to healthy controls ([Fig. 1](#f0005){ref-type="fig"}). Non-carriers exhibited similar but more extensive bilateral atrophy in the frontotemporal, insular, cingulate and striatal regions. *C9orf72* expansion carriers showed atrophy in bilateral precuneus and posterior cingulate cortex (not affected in *C9orf72* non-carriers), whereas *C9orf72* non-carriers (but not *C9orf72* expansion carriers) showed atrophy in the cerebellum. Direct comparisons between *C9orf72* carriers and non-carriers did not reveal regions of significant differences between groups.

### 3.3.2. Neural correlates of psychosis {#s0090}

A higher psychosis score for all participants combined (bvFTD and FTD-ALS) was associated with volume loss in a network of cortical and subcortical regions. The regions implicated included the bilateral medial prefrontal and occipital cortices, and the right thalamus and the left cerebellum ([Fig. 2](#f0010){ref-type="fig"} and Supplementary Table e2).

In *C9orf72* expansion carriers, higher psychosis scores correlated with grey matter volume loss in a broader network of regions including bilateral medial frontal cortex, anterior cingulate cortex and orbitofrontal cortex, bilateral insula, caudate, putamen and thalamic nuclei, middle, inferior and superior temporal gyrus, temporal fusiform gyrus, lateral occipital cortex and right cerebellum ([Fig. 3](#f0015){ref-type="fig"} and Supplementary Table e3).

4. Discussion {#s0095}
=============

Delusions and hallucinations in the FTD-ALS continuum have received renewed interest following the discovery of the *C9orf72* expansion as the most common genetic abnormality in FTD and FTD-ALS ([@bb0070], [@bb0180]). First, by means of a prospective study design, this study has confirmed that psychosis is common and can be more severe than previously recognised in patients with FTD. The rate of psychotic features was higher in *C9orf72* carriers than non-carriers and these symptoms were more marked in such cases as reflected by the significantly higher psychosis index. Of interest, this is the first study to explore the patterns of brain atrophy associated with psychosis in *C9orf72* FTD-ALS. A distributed network of cortical and subcortical regions was identified, that included discrete regions of the frontal temporal and occipital cortices, as well as the thalamus, striatum and cerebellum. These patterns are strikingly similar to the changes seen in grey matter in schizophrenia and other psychotic disorders.

Over one-third of the study cohort exhibited a degree of psychosis at first presentation, in contrast to previous studies where lower rates have been reported, and also slightly higher than recent systematic reviews have suggested ([@bb0110], [@bb0200]), but in line with a recent study which identified psychotic symptoms in 32% of FTD patients by means of a retrospective chart review. This discrepancy may be partly explained by case selection; in our cohort we included only those with bvFTD and FTD-ALS and in these cohorts psychosis is generally considered to be more common ([@bb0135]). The use of a face-to-face focused carer and patient interview allowed for better delineation of symptoms. Of course the nature of referral patterns and referral bias to tertiary centres must always be taken into consideration and these results may not be readily transferrable to the population as a whole. Nonetheless, these results highlight the extent of psychosis in FTD and particularly the need for more effective treatments for these symptoms.

Overall, the delusions and hallucinations in these patients were largely negative in nature, and were not in keeping with the patients\' previous life experiences. It could be argued that these delusions represent confabulation related to frontal inhibitory dysfunction and 'filling in the gaps' of memory loss which occurs in FTD ([@bb0150]). The relative lack of grandiose delusions plus the pervasive nature of the delusions makes this unlikely. It is also difficult to differentiate true somatic hallucinations from medically unexplained symptoms, which often have a complex psychosocial basis. Moreover, abnormalities in perception, specifically auditory and temperature perception, related to underlying brain atrophy have been documented in these conditions ([@bb0090], [@bb0105]). In the absence of more sensitive measures of psychosis it is difficult to determine the relationship between psychotic symptoms, medically unexplained symptoms and perceptual changes. Of interest is also the finding that the rate of hallucinations did not differ between carriers and non-carriers. This might merely reflect the relatively small numbers of patients with hallucinations but also suggests a disassociation between the mechanisms involved in the generation of delusions and hallucinations in FTD-ALS and warrants further study in a larger cohort. It has recently been reported that patients with ALS can experience non-psychotic primary psychiatric disorders years before the first diagnosis of ALS and while anecdotally a similar pattern is seen in patients with the *C9orf72* expansion, this has not yet been systematically reviewed but might offer some insight into the underlying neurobiology which renders some patients more susceptible to developing psychiatric symptoms ([@bb0215]).

Until now the neural correlates of psychosis in FTD have been relatively unexplored. A recent study utilized pathological data to correlate regions of atrophy at post-mortem to psychotic symptoms reported at any time during life, and found an association with predominantly right-sided brain degeneration but failed to find any link with subcortical atrophy ([@bb0120]). Methodological differences may explain the divergent findings between this recent study and the current study. Although the current study did not have the benefit of pathological disease confirmation, a major strength is that after detailed clinical phenotyping each patient underwent MRI scanning within 2 days, therefore ensuring that the patterns of brain atrophy best reflected the symptoms experienced by the patient at that time. Furthermore, in the current cohort there were no differences between patients who experienced psychotic symptoms and those who did not in terms of other abnormal behaviours, such as disinhibition and apathy, suggesting that the results are not driven by other behavioural factors.

The association of a network of cortical and subcortical atrophy with increased psychosis scores in *C9orf72* is new and a key finding of this study. The findings are exploratory however they do converge with the hypothesis of Downey and colleagues who showed that *C9orf72* carriers have an altered body schema ([@bb0085]). These authors suggested that altered body schema deficits might contribute to the development of psychosis generation in *C9orf72* carriers through alterations in thalamo-cortico-cerebellar networks. The regions of atrophy identified here are remarkably similar to those identified consistently in meta-analyses of VBM studies of schizophrenia and other psychotic disorders including schizoaffective disorder and first-episode psychosis ([@bb0010], [@bb0050], [@bb0100]). Similar to our findings, these meta-analyses repeatedly show atrophy of key temporal lobe structures including the superior temporal gyrus, which has also been linked with positive symptoms and in particular auditory hallucinations in schizophrenia ([@bb0005]). Atrophy of the insular and anterior cingulate cortex are associated with higher psychosis scores in our cohort and again these regions, which are key structures of the salience network with links to the superior temporal pole, the dorsolateral prefrontal cortex, thalamus, and the striatum ([@bb0195]), are shown to be atrophied across multiple VBM studies in psychotic syndromes ([@bb0010], [@bb0050], [@bb0100]). The salience network is involved in detection, analysis and integration of emotionally salient stimuli with respect to the internal environment and is implicated in symptom generation in both FTD and schizophrenia ([@bb0195], [@bb0230]). Similarly, and consistent with the findings from this study, within the frontal cortex the medial frontal region is characteristically abnormal in psychotic disorders. That the thalamus has been repeatedly implicated in psychotic disorders converges well with previous imaging findings in *C9orf72* carriers, which showed thalamic atrophy, and thalamic involvement in functional networks ([@bb0125], [@bb0145]).

This study has limitations. Replication in a larger cohort is necessary to increase statistical power and confirm the findings, although given the relative rarity of these conditions this can be difficult, which in turn points to the need for multicentre collaborations. The neuroimaging findings, although novel, are preliminary and further neuroimaging projects should include methods of analysing network connectivity to confirm if dysfunctions within large-scale brain networks are responsible for psychosis in FTD. It is also important to note that subregions within subcortical structures, such as the thalamus, have distinct functions and map to specific cortical region. Analysis of these subregions was beyond the scope of this study but should be considered for future projects. Furthermore, analysis of delusions and hallucinations separately would have been ideal, as it is possible that these two symptoms may have different neural circuitry. However the small sample size restricted further analysis and therefore was outside the scope of this project but should be performed in a larger cohort in future studies.

In conclusion, psychotic symptoms are common in the FTD-ALS continuum, and should be assessed by means of a detailed carer and patient interview. The commonalities between primary psychotic disorders and the FTD-ALS continuum in terms of underlying neural substrates are notable, and in line with current views that brain network degeneration may be responsible for shared behavioural symptoms between schizophrenia and FTD ([@bb0230]), which further suggests that we may be able to incorporate patient management strategies from psychiatry. Finally, we suggest that an objective measure to characterise psychotic symptoms will be useful as well as targeted studies using functional MRI to gain further insight into the brain networks involved.
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![Regions of brain atrophy in *C9orf72* carriers and non-carriers compared to healthy controls.\
Group results from voxel-based morphometry analyses demonstrating areas of decreased grey matter density in *C9orf72* positive (blue) and *C9orf72* negative (yellow) relative to healthy controls. Patient groups showed extensive overlapping atrophy (green). Significant clusters were defined at a t-threshold corrected for family-wise error of *p* \< 0.05 with a minimum cluster size of 50 voxels. No significant clusters were identified in direct comparisons between negative and positive *C9orf72* patients. The statistical maps are superimposed on the Montreal Neurological Institute template brain. Images are displayed in radiological convention (the left side of images corresponds to the right side of the brain). C9 pos = *C9orf72* positive; C9 neg = *C9orf72* negative; HC = healthy controls.](gr1){#f0005}

![Neural correlates of psychosis in the FTD-ALS continuum.\
Results from voxel-based morphometry analyses demonstrating correlations between psychosis index and areas of grey matter density in the whole FTD-ALS cohort. The statistical maps are superimposed on the Montreal Neurological Institute template brain. Coloured voxels show regions that were significant in the analyses (*p* \< 0.005 uncorrected). Images are displayed in radiological convention (the left side of image corresponds to the right side of the brain).](gr2){#f0010}

![Neural correlates of psychosis in *C9orf72* expansion carriers.\
Results from voxel-based morphometry analyses demonstrating correlations between psychosis index and areas of grey matter density in *C9orf72* expansion carriers. The statistical maps are superimposed on the Montreal Neurological Institute template brain. Coloured voxels show regions that were significant in the analyses (*p* \< 0.005 uncorrected). Images are displayed in radiological convention (the left side of image corresponds to the right side of the brain).](gr3){#f0015}

###### 

Demographics and clinical characteristics in bvFTD, FTD-ALS and healthy controls, and *C9orf72* carriers and non-carriers.

Table 1

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                     bvFTD\        FTD-ALS\      HC\          *p* value                                    Post-hoc               *C9orf72* carriers\   *C9orf72* non-carriers\   *p* value
                                                     (n = 36)      (n = 20)      (n = 23)                                                                         (n = 14)              (n = 42)                  
  -------------------------------------------------- ------------- ------------- ------------ -------------------------------------------- ---------------------- --------------------- ------------------------- -----------
  *C9orf72* positive, n (%)                          9 (25%)       5 (25%)       0            --                                           --                     --                    --                        --

  Sex (M:F)                                          26:12         13:7          14:9         0.65                                         --                     11:3                  28:14                     0.5

  Age (years)                                        59 ± 7.2      60.6 ± 6.6    62.5 ± 3.9   0.37                                         --                     61.2 ± 5.9            59.1 ± 7.1                0.4

  Education (years)                                  12.8 ± 3.4    12.6 ± 3.0    12.6 ± 2.9   0.47                                         --                     12.6 ± 2.8            12.8 ± 3.5                0.83

  Disease duration (years)                           3.7 ± 2.4     2.5 ± 1.2     --           0.08                                         --                     4.2 ± 2.6             3.1 ± 2.0                 0.2

  ACE-R (max 100)                                    73.5 ± 13.4   68.7 ± 12.3   94.1 ± 3.8   \< 0.001[⁎⁎](#tf0015){ref-type="table-fn"}   HC \> bvFTD, FTD-ALS   73.8 ± 17.1           71.7 ± 12.5               0.3

  FRS Rasch score[a](#tf0005){ref-type="table-fn"}   − 0.7 ± 1.3   0.7 ± 1.7     --           0.007[⁎](#tf0010){ref-type="table-fn"}       --                     − 0.03 ± 1.7          − 0.34 ± 1.6              0.72
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are expressed as mean ± standard deviation. bvFTD = behavioural variant frontotemporal dementia; FTD-ALS = frontotemporal dementia -- amyotrophic lateral sclerosis; HC = healthy controls; ACE-R = Addenbrooke\'s Cognitive Examination -- Revised; FRS = Functional dementia Rating Scale.

The FRS provides logit scores ranging from 4.12 (very mild) to − 4.99 (very severe).

Denotes significant differences at the *p* \< 0.05 level.

Denotes significant differences at the *p* \< 0.001 level.

###### 

Psychosis scores and characterisation of psychotic symptoms in *C9orf72* positive and negative patients.

Table 2

                              *C9orf72* positive (n = 14)   *C9orf72* negative (n = 42)   *p* value
  --------------------------- ----------------------------- ----------------------------- ----------------------------------------
  Psychosis score             5.3 ± 5.3                     1.9 ± 4.6                     0.002[⁎](#tf0020){ref-type="table-fn"}
  Psychosis index             24.3 ± 22                     7.7 ± 19.5                    0.002[⁎](#tf0020){ref-type="table-fn"}
  Psychotic symptoms, n (%)   9 (64)                        11 (26)                       0.006[⁎](#tf0020){ref-type="table-fn"}
   Delusions                  8 (57)                        8 (19)                        0.006[⁎](#tf0020){ref-type="table-fn"}
   Persecutory                4 (29)                        6 (14)                        0.04[⁎](#tf0020){ref-type="table-fn"}
   Somatic                    3 (21)                        2 (5)                         0.06
   Jealous                    2 (14)                        1 (2)                         0.08
   Grandiose                  2 (14)                        2 (5)                         0.23
   Hallucinations             5 (36)                        9 (17)                        0.133
   Auditory                   3 (21)                        2 (5)                         0.06
   Visual                     2 (14)                        3 (7)                         0.42
   Somatic                    1 (7)                         1 (2)                         0.41

Values are expressed as mean ± standard deviation.

Denotes significant differences at the *p* \< 0.05 level.
